316 related articles for article (PubMed ID: 19021293)
1. Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease.
Guan H; Liu Y; Daily A; Police S; Kim MH; Oddo S; LaFerla FM; Pauly JR; Murphy MP; Hersh LB
J Neurosci Res; 2009 May; 87(6):1462-73. PubMed ID: 19021293
[TBL] [Abstract][Full Text] [Related]
2. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.
Meilandt WJ; Cisse M; Ho K; Wu T; Esposito LA; Scearce-Levie K; Cheng IH; Yu GQ; Mucke L
J Neurosci; 2009 Feb; 29(7):1977-86. PubMed ID: 19228952
[TBL] [Abstract][Full Text] [Related]
3. Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice.
Spencer B; Marr RA; Rockenstein E; Crews L; Adame A; Potkar R; Patrick C; Gage FH; Verma IM; Masliah E
BMC Neurosci; 2008 Nov; 9():109. PubMed ID: 19014502
[TBL] [Abstract][Full Text] [Related]
4. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.
Hemming ML; Patterson M; Reske-Nielsen C; Lin L; Isacson O; Selkoe DJ
PLoS Med; 2007 Aug; 4(8):e262. PubMed ID: 17760499
[TBL] [Abstract][Full Text] [Related]
5. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
[TBL] [Abstract][Full Text] [Related]
6. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
[TBL] [Abstract][Full Text] [Related]
7. Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice.
Park MH; Lee JK; Choi S; Ahn J; Jin HK; Park JS; Bae JS
Brain Res; 2013 Sep; 1529():113-24. PubMed ID: 23831521
[TBL] [Abstract][Full Text] [Related]
8. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function.
Huang SM; Mouri A; Kokubo H; Nakajima R; Suemoto T; Higuchi M; Staufenbiel M; Noda Y; Yamaguchi H; Nabeshima T; Saido TC; Iwata N
J Biol Chem; 2006 Jun; 281(26):17941-51. PubMed ID: 16636059
[TBL] [Abstract][Full Text] [Related]
9. Neprilysin regulates amyloid Beta peptide levels.
Marr RA; Guan H; Rockenstein E; Kindy M; Gage FH; Verma I; Masliah E; Hersh LB
J Mol Neurosci; 2004; 22(1-2):5-11. PubMed ID: 14742905
[TBL] [Abstract][Full Text] [Related]
10. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease.
El-Amouri SS; Zhu H; Yu J; Marr R; Verma IM; Kindy MS
Am J Pathol; 2008 May; 172(5):1342-54. PubMed ID: 18403590
[TBL] [Abstract][Full Text] [Related]
11. A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice.
Devi L; Ohno M
Mol Brain; 2015 Mar; 8():19. PubMed ID: 25884928
[TBL] [Abstract][Full Text] [Related]
12. γ-Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer's disease.
Klein C; Mathis C; Leva G; Patte-Mensah C; Cassel JC; Maitre M; Mensah-Nyagan AG
Neurobiol Aging; 2015 Feb; 36(2):832-44. PubMed ID: 25457559
[TBL] [Abstract][Full Text] [Related]
13. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice.
Marr RA; Rockenstein E; Mukherjee A; Kindy MS; Hersh LB; Gage FH; Verma IM; Masliah E
J Neurosci; 2003 Mar; 23(6):1992-6. PubMed ID: 12657655
[TBL] [Abstract][Full Text] [Related]
14. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology.
Fukami S; Watanabe K; Iwata N; Haraoka J; Lu B; Gerard NP; Gerard C; Fraser P; Westaway D; St George-Hyslop P; Saido TC
Neurosci Res; 2002 May; 43(1):39-56. PubMed ID: 12074840
[TBL] [Abstract][Full Text] [Related]
15. Self-assembling nanofibers alter the processing of amyloid precursor protein in a transgenic mouse model of Alzheimer's disease.
Yang H; Yang H; Xie Z; Wang P; Bi J
Neurol Res; 2015 Jan; 37(1):84-91. PubMed ID: 25005263
[TBL] [Abstract][Full Text] [Related]
16. Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer's disease.
Rofo F; Metzendorf NG; Saubi C; Suominen L; Godec A; Sehlin D; Syvänen S; Hultqvist G
Alzheimers Res Ther; 2022 Dec; 14(1):180. PubMed ID: 36471433
[TBL] [Abstract][Full Text] [Related]
17. Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer's Disease.
Sikanyika NL; Parkington HC; Smith AI; Kuruppu S
Neurochem Res; 2019 Jun; 44(6):1289-1296. PubMed ID: 30806879
[TBL] [Abstract][Full Text] [Related]
18. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain.
Iwata N; Mizukami H; Shirotani K; Takaki Y; Muramatsu S; Lu B; Gerard NP; Gerard C; Ozawa K; Saido TC
J Neurosci; 2004 Jan; 24(4):991-8. PubMed ID: 14749444
[TBL] [Abstract][Full Text] [Related]
19. Effect of Tong Luo Jiu Nao on Aβ-degrading enzymes in AD rat brains.
Liu Y; Hua Q; Lei H; Li P
J Ethnopharmacol; 2011 Sep; 137(2):1035-46. PubMed ID: 21798326
[TBL] [Abstract][Full Text] [Related]
20. 4-O-methylhonokiol attenuated memory impairment through modulation of oxidative damage of enzymes involving amyloid-β generation and accumulation in a mouse model of Alzheimer's disease.
Choi IS; Lee YJ; Choi DY; Lee YK; Lee YH; Kim KH; Kim YH; Jeon YH; Kim EH; Han SB; Jung JK; Yun YP; Oh KW; Hwang DY; Hong JT
J Alzheimers Dis; 2011; 27(1):127-41. PubMed ID: 21799245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
